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SHORT REPORT

Frontline polatuzumab vedotin for diffuse large B-cell
lymphoma: A survey of clinician impressions
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Abstract
In the POLARIX trial, pola-R-CHP demonstrated improved progression-free survival
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(PFS) compared to R-CHOP in untreated intermediate- to high-risk DLBCL. We
surveyed practicing clinicians regarding their interpretation of POLARIX, including
impressions of efficacy, safety, and cost. Of 174 respondents, most from academic centers (82%) in the United States (57%), 70% stated they would not replace R-CHOP
with pola-R-CHP due to insufficient PFS difference, lack of overall survival benefit,
and excessive cost. Respondents not recommending pola-R-CHP expressed concerns
about financial implications for both society and patients. We observed considerable
heterogeneity in both study interpretation and plans for real-world implementation of
pola-R-CHP.
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Treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL)

antibody–drug conjugate polatuzumab vedotin) versus R-CHOP. It

has remained largely unchanged for 20 years since rituximab was

enrolled adults with untreated intermediate-/high-risk DLBCL (defined

added to the backbone of cyclophosphamide, doxorubicin, vincristine,

by International Prognostic Index [IPI] score ≥2), with PFS as its

and prednisone (R-CHOP) [1]. Several randomized controlled tri-

primary endpoint and overall survival (OS) and safety as secondary

als have sought to improve upon R-CHOP [2], including intensified

endpoints. POLARIX met its primary endpoint of improved PFS,

chemotherapy, post-R-CHOP maintenance, and novel therapies added

with no new safety signals and immature OS data, when the find-

to R-CHOP [3]. Most of these trials did not meet their endpoint of

ings were presented at the American Society of Hematology Annual

improved progression-free survival (PFS), and none became standard-

Meeting and simultaneously published in December 2021. Given the

of-care [4]. Most recently, the POLARIX study [5], an international,

potential for pola-R-CHP to replace R-CHOP as standard frontline

double-blind, placebo-controlled randomized phase 3 trial, evaluated

treatment for DLBCL, we conducted a survey of practicing clini-

pola-R-CHP (replacing vincristine in R-CHOP with the anti-CD79b

cians to understand their real-world interpretation of the POLARIX
results, including impressions of the efficacy, safety, and cost of
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pola-R-CHP.
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TA B L E 1

Demographics and diffuse large B-cell lymphoma (DLBCL) practice patterns of survey respondents
Total
(N = 174)

%

139

82%

8

5%

18

11%

5

3%

USA

86

57%

Spain

13

9%

Survey question
Which best describes the healthcare setting in which you work? (N = 170)
Academic health system
Private practice
Hybrid model (private with academic affiliation)
Other
In what country are you based? (N = 150)

UK

13

9%

Australia

12

8%

4

3%

Canada
India

4

3%

Saudi Arabia

3

2%

Czechia

2

1%

France

2

1%

Switzerland

2

1%

Brazil

1

1%

Chile

1

1%

Germany

1

1%

Iraq

1

1%

Ireland

1

1%

Israel

1

1%

New Zealand

1

1%

Sweden

1

1%

Thailand

1

1%

What is your degree? (N = 172)
MD, DO, MBBS, MBChB, or equivalent

118

69%

40

23%

PharmD or other pharmacy degree

9

5%

NP (i.e., APN, DNP, or equivalent)

3

2%

PA

1

1%

Other

1

1%

72

42%

Hematologist/medical oncologist

61

35%

Hematology, oncology, or hematology/oncology fellow

15

9%

Medical oncologist

13

8%

MD and PhD

What type of clinician are you? (N = 172)
Hematologist

Pharmacist

9

5%

Radiation oncologist

1

1%

Other

1

1%

In total, how many years have you been taking care of patients with lymphoma? (N = 167)
Median
Range

10
1.5–40

(Continues)
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TA B L E 1

(Continued)
Total
(N = 174)

Survey question

%

Approximately how many patients with DLBCL do you see per week? (N = 167)
Median

5

Range

0–70

What is the extent of your participation in clinical trials specifically enrolling patients with DLBCL? Select all that apply (N = 174)
PI

75

43%

Coinvestigator

80

46%

Local site PI

79

45%

Enroll patients onto clinical trials

85

49%

None of the above

27

16%

What is your preferred strategy for treating patients with newly diagnosed early-stage (Ann-Arbor I–II, non-bulky) DLBCL? (N = 166)
R-CHOP × 4 cycles

63

38%

R-CHOP × 3 cycles followed by ISRT

58

35%

R-CHOP × 6 cycles ± ISRT

27

16%

Other

18

11%

How do you generally treat newly diagnosed advanced-stage (Ann Arbor III–IV) double expressor (negative for MYC rearrangement) DLBCL? (N = 165)
R-CHOP × 6 cycles
Dose-adjusted R-EPOCH × 6 cycles
Other

146

88%

13

8%

6

4%

How do you generally treat newly diagnosed advanced-stage high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (also known
as “double-hit” or “triple-hit” lymphoma)? (N = 166)
R-CHOP × 6 cycles
Dose-adjusted R-EPOCH × 6 cycles
Other

39

23%

111

67%

16

10%

Do you use CNS prophylaxis in patients with DLBCL and a high CNS-IPI score (i.e., several extranodal sites, kidney/adrenal involvement), and if so, what is
your preferred strategy? (N = 165)
Yes, and I prefer IT methotrexate

28

17%

Yes, and I prefer IV high-dose methotrexate

78

47%

Yes, but I have no inherent preference between IT and IV methotrexate

15

9%

No, I do not routinely consider CNS prophylaxis in this setting

35

21%

9

5%

Other

What is your clinical experience so far treating patients with relapsed or refractory DLBCL with polatuzumab vedotin? (N = 166)
I have had generally good outcomes

36

22%

I have had a mix of good and poor outcomes

80

48%

I have had generally poor outcomes

20

12%

I have not used polatuzumab vedotin in the relapsed or refractory setting

27

16%

3

2%

Other

Abbreviations: CNS, central nervous system; IPI, International Prognostic Index; ISRT, involved-site radiation therapy; IT, intrathecal; IV, intravenous; PI,
principal investigator.

We developed an electronic survey that included clinician demo-

was approved by Washington University in St. Louis Human Research

graphics, DLBCL practice patterns, a discrete-choice experiment (DCE)

Protection Office. Free-text responses were qualitatively coded in

comparing R-CHOP with a hypothetical regimen “S-FLOP,” and percep-

consensus by two authors.

tions regarding pola-R-CHP. The survey was open from January 11 to

Of 302 subjects who opened the survey, 174 (58%) consented

February 20, 2022, and distributed via email and social media to aca-

to participation and had response data available. The majority of

demic medical centers, private practice groups, and lymphoma-focused

respondents worked in an academic health system (82%), were located

professional societies. The survey, available in Supporting Information,

in the United States (US, 57%), were medical doctorates (69%),
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TA B L E 2

Impressions about the results of the POLARIX study by survey respondents
Total
(N = 174)

%

Yes

131

96%

No

6

4%

Survey question
Are you familiar with the results of the POLARIX study? (N = 137)

Do you plan to replace R-CHOP with pola-R-CHP in your practice for patients with newly diagnosed DLBCL? (N = 145)
Yes

43

30%

No

102

70%

Does information about overall response and complete response rates change your previously expressed impression of pola-R-CHP compared to
R-CHOP? (N = 145)
Yes

6

4%

No

139

96%

With this information about safety and toxicities in the POLARIX study, how do you view the toxicity profiles of pola-R-CHP and R-CHOP? (N = 144)
Pola-R-CHP is significantly more toxic than R-CHOP

2

1%

Pola-R-CHP is mildly more toxic than R-CHOP

52

36%

Pola-R-CHP and R-CHOP have similar toxicity profiles

87

60%

R-CHOP is mildly more toxic than pola-R-CHP

3

2%

R-CHOP is significantly more toxic than pola-R-CHP

0

0%

Which of the following statements best describes how the toxicity profile of pola-R-CHP influences your thoughts on utilizing this regimen instead of
R-CHOP? (N = 145)
The toxicity profile of pola-R-CHP makes me more likely to utilize it in place of R-CHOP

24

17%

Irrespective of the toxicity profile of pola-R-CHP, I plan to utilize it in place of R-CHOP due to
impressive efficacy outcomes

17

12%

Irrespective of the toxicity profile of pola-R-CHP, I do not plan to utilize it in place of R-CHOP
due to underwhelming efficacy outcomes

73

50%

The toxicity profile of pola-R-CHP makes me less likely to utilize it in place of R-CHOP

19

13%

Other

12

8%

Based on your impression of the information presented thus far, what would be a fair cost for one cycle of pola-R-CHP? (N = 146)
Greater than $20,000 USD

10

7%

$15,000–$20,000 USD

11

8%

$10,000–$15,000 USD

38

26%

$8000–$10,000 USD

56

38%

$7000 USD (the same as R-CHOP)

27

18%

4

3%

Other

Based on the information presented thus far about the cost of one cycle of pola-R-CHP, do you plan to replace R-CHOP with pola-R-CHP in your practice
for patients with newly diagnosed DLBCL? (N = 140)
Yes

32

23%

No

108

77%

How do the financial implications of offering pola-R-CHP to your patients with DLBCL influence your decision to offer it over R-CHOP? (N = 140)
A. I definitely will offer pola-R-CHP irrespective of the financial implications

22

16%

B. I am hesitant to offer pola-R-CHP due to financial implications for society and my country’s
healthcare system at-large

33

24%

C. I am hesitant to offer pola-R-CHP due to financial implications for my patients specifically

11

8%

Both B and C

29

21%

D. I am hesitant to offer pola-R-CHP irrespective of the financial implications because of
concerns about the POLARIX trial design, endpoints, and/or outcomes

29

21%

E. None of the above apply to me

16

11%

(Continues)
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TA B L E 2

(Continued)
Total
(N = 174)

Survey question

%

Does this information regarding exploratory subgroup analyses influence your previously expressed opinions? (N = 140)
Yes

62

44%

No

78

56%

Before considering a change in your typical management of patients with newly diagnosed advanced-stage DLBCL, which of the following options is
closest to your desired minimum NNT with a regimen other than R-CHOP to achieve one additional cure with frontline therapy? (N = 139)
5

14

10%

10

32

23%

15

18

13%

20

12

9%

30

3

2%

57

41%

3

2%

I do not routinely think about NNT in this context
Other

In POLARIX, approximately 17 patients needed to receive pola-R-CHP to cure one additional patient with frontline therapy, at an approximate cost of
$1.6 million USD to the healthcare system. The NNT to avoid one additional patient having to undergo autologous stem-cell transplantation was 32
(approximately $3.1 million), and to avoid one additional patient having to undergo CAR T-cell therapy was 63 (approximately $6 million, based on CAR T
use in the third-line setting). How does this information influence your views? (N = 137)
I am much more likely to offer pola-R-CHP over R-CHOP

6

4%

I am somewhat more likely to offer pola-R-CHP over R-CHOP

19

14%

My views are not influenced by these data

64

47%

I am somewhat less likely to offer pola-R-CHP over R-CHOP

31

23%

I am much less likely to offer pola-R-CHP over R-CHOP

17

12%

Abbreviations: CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; NNT, number needed to treat.

and identified as hematologists (42%) or hematologist–oncologists

insufficient PFS difference, lack of OS benefit demonstrated to date,

(35%) (Table 1). Respondents, nearly half of whom were involved in

and excessive costs. Sixty percent of respondents felt that pola-R-CHP

DLBCL clinical trials, had a median of 10 years of clinical experience

and R-CHOP had similar toxicity profiles, whereas 36% felt that

treating patients with lymphoma and saw a median of five patients

pola-R-CHP was mildly more toxic. Many respondents did not plan

with DLBCL per week. Regarding contemporary practice patterns,

to use pola-R-CHP regardless of the toxicity profile (50%) due to

most respondents used intensified therapy for double-/triple-hit

underwhelming efficacy.

lymphoma (67%), and many utilized high-dose methotrexate for cen-

When presented with approximate costs-per-cycle of pola-R-CHP,

tral nervous system (CNS) prophylaxis in patients with high CNS-IPI

23% of all respondents indicated they would replace R-CHOP with

scores (47%). Most respondents had a mix of good and poor clinical

pola-R-CHP (Table 2). Free-text responses revealed that these respon-

experiences with polatuzumab vedotin in the relapsed DLBCL setting

dents felt that PFS benefits superseded cost concerns and that physi-

(48%).

cians are not responsible for determining acceptable costs, whereas

When presented with a hypothetical new frontline DLBCL regimen

those who did not recommend pola-R-CHP felt that the PFS benefit

“S-FLOP” with a 15% absolute improvement in 2-year PFS but no dif-

was underwhelming relative to the excessive cost and that the regimen

ference in OS compared to R-CHOP, most respondents chose “S-FLOP”

would not be available owing to lack of reimbursement or approval.

over R-CHOP (78%). Respondents ranked OS as the most important

Most commonly, respondents were hesitant to offer pola-R-CHP due

consideration in adopting “S-FLOP,” followed by PFS and adverse

to financial implications for society (24%) or financial implications for

events. Additional costs of “S-FLOP,” patient-reported outcomes, and

society and patients (29%).

subsequent therapies were ranked as less important. If “S-FLOP” was

Regarding exploratory subgroup analyses of POLARIX demonstrat-

twice as expensive as R-CHOP, 52% recommended “S-FLOP” over

ing PFS benefit in patients with activated B-cell (ABC) DLBCL, 56% of

R-CHOP. When the PFS benefit changed to 5%, with twice the cost,

respondents stated that this information did not influence their pre-

only 20% recommended “S-FLOP.”

vious opinions about pola-R-CHP; many felt that definitive decisions

In response to the PFS and OS results from POLARIX, 30% of

could not be made based on underpowered subgroup analyses. Many

respondents stated they would replace R-CHOP with pola-R-CHP

respondents did not routinely use the number needed to treat (NNT)

(Table 2). In the analysis of the free-text responses, respondents who

for PFS in decision-making about frontline DLBCL management (41%),

recommended pola-R-CHP stated that the PFS benefit was important,

and their opinions regarding pola-R-CHP were not influenced when

whereas those who did not recommend pola-R-CHP highlighted an

presented with NNT data for pola-R-CHP (47%).
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Unlike other malignancies [6, 7], PFS substantially reflects the
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